Alliance for Pandemic Preparedness

May 6, 2021

Impact and Effectiveness of MRNA BNT162b2 Vaccine against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance Data

Category:

Topic:

Keywords (Tags):

  • Estimated real-world vaccine effectiveness 7 days or more after the second dose of the Pfizer-BioNTech vaccine was 95% against SARS-CoV-2 infection according to analysis of national surveillance data from Israel (n=4.7 million) between January to April 2021After adjustment for age, sex, and week of infection, estimated vaccine effectiveness was 92% against aymptomatic infection and 97% against symptomatic infection. The authors calculated that vaccination lead to a 97% reduction in COVID-19-related hospitalization and a 97% reduction in i COVID-19-related death. 95% of tested specimens from a nationwide convenience sample (n=8,472) during the analysis period showed spike gene target failure, indicating a high prevalence of infections caused by the B.1.1.7 variant.

Haas et al. (May 6, 2021). Impact and Effectiveness of MRNA BNT162b2 Vaccine against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance Data. The Lancet. https://doi.org/10.1016/S0140-6736(21)00947-8